Effect of Peas in Soup on Blood Glucose Control

Not Applicable

Active, not recruiting

• Conditions: Post-prandial Glycaemia
• Interventions: Dietary Supplement: Split yellow pea soup; Dietary Supplement: Whole yellow pea soup; Dietary Supplement: Potato soup

• Registration Number: NCT03306862
• Lead Sponsor: St. Boniface Hospital

Brief Summary

This study is part of a group of studies whose overall goal is to accurately define the physiochemical and structural effects of pea varieties and relate these to blood glucose attenuation in healthy human volunteers.

Detailed Description

A randomized, controlled, cross-over study designed to examine the post-prandial glycaemic response to peas in soup will be conducted at the I.H. Asper Clinical Research Institute in Winnipeg, Manitoba. Eligible participants who have provided consent will be asked to attend 3 clinic visits in a fasted state. Participants will be given soup containing peas at 2 visits and soup without peas at 1 visit. At each visit participants will provide 7 capillary blood samples via finger poke, 5 questionnaires about their appetite and a questionnaire about the acceptability of the products. Each visit will last approximately 2.5h and be separated by 3-14 days.

Study Timeline

• Study First Submitted: 2017-10-02
• Study First Submitted QC: 2017-10-05
• Study First Posted: 2017-10-11
• Study Start: 2017-11-08
• Primary Completion: 2018-12-21
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-26
• Last Update Posted: 2024-11-29
• Study Completion: 2025-01

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Generally healthy male or female, between the age of 18-40 years;
2. Body mass index (BMI) 18.5-30.0 kg/m2;
3. Habitually consume breakfast, lunch and dinner in the morning, mid-day and evening, respectively.
4. Willing to provide informed consent;
5. Willing/able to comply with the requirements of the study.

Exclusion Criteria

1. Pregnant or lactating;
2. Medical history of diabetes mellitus, fasting blood glucose ≥6.1 mmol/L, HbA1c ≥6.0%, or use of insulin or oral medication to control blood sugar;
3. Medical history of cardiovascular disease;
4. Systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg;
5. Fasting plasma total cholesterol >7.8 mmol/L;
6. Fasting plasma HDL <0.9 mmol/L;
7. Fasting plasma LDL >5.0 mmol/L;
8. Fasting plasma triglycerides >2.3 mmol/L;
9. Major surgery within the last 3 months;
10. Medical history of inflammatory disease (ie. Systemic lupus erythematosis, rheumatoid arthritis, psoriasis) or use of any corticosteroid medications within 3 months;
11. Medical history of liver disease or liver dysfunction (defined as plasma AST or ALT ≥1.5 times the upper limit of normal (ULN));
12. Medical history of kidney disease or kidney dysfunction (defined as blood urea nitrogen and creatinine ≥ 1.8 times the ULN));
13. Presence of a gastrointestinal disorder, daily use of any stomach acid-lowering medications or laxatives (including fibre supplements) within the past month or antibiotic use within the past 6 weeks;
14. Active treatment for any type of cancer within 1 year prior to study start;
15. Shift worker (a system of employment where an individual's normal hours of work are in part, outside the period of normal working day; 6am and 8pm);
16. Smoking, use of tobacco or a nicotine replacement product (within the last 3 months);
17. Allergies to peas;
18. Aversion or unwillingness to eat study foods;
19. Consuming >4 servings of pulses per week;
20. Use of any prescription or non-prescription drug, herbal or nutritional supplement known to affect glycaemia or appetite;
21. Participation in another clinical trial, current or in the past 4 weeks;
22. Unstable body weight (defined as >5% change in 3 months) or actively participating in a weight loss program.
23. Other medical, psychiatric, or behavioral factors that in the judgment of the principal Investigator may interfere with study participation or the ability to follow the intervention protocol;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Split yellow pea	Split yellow pea soup	Soup containing 25g available carbohydrates from split yellow peas. Intervention: Split yellow pea soup
Whole yellow pea	Whole yellow pea soup	Soup containing 25g available carbohydrates from whole yellow peas. Intervention: Whole yellow pea soup
Potato	Potato soup	Soup containing 25g available carbohydrates from potatoes. Intervention: Potato soup

Primary Outcome Measures

Name	Time	Method
Post-prandial glucose	120 min	iAUC for glucose
Post-prandial insulin	120 min	iAUC for insulin

Secondary Outcome Measures

Name	Time	Method
Fullness	120 min	AUC using visual analog scales
Desire to eat	120 min	AUC using visual analog scales
Prospective consumption	120 min	AUC using visual analog scales
Hunger	120 min	AUC using visual analog scales

Trial Locations

Locations (1)

I.H. Asper Clinical Research Institute; 🇨🇦 Winnipeg, Manitoba, Canada